Zacks Investment Research upgraded shares of Neos Therapeutics (NASDAQ:NEOS) from a hold rating to a buy rating in a report published on Thursday, Zacks.com reports. The brokerage currently has $1.50 price objective on the stock.
According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
A number of other equities research analysts also recently issued reports on the company. ValuEngine downgraded Zosano Pharma from a buy rating to a hold rating in a research report on Wednesday, May 1st. Cantor Fitzgerald reissued an overweight rating and set a $130.00 price target (up previously from $116.00) on shares of Zoetis in a research report on Wednesday, June 12th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. Neos Therapeutics currently has a consensus rating of Hold and a consensus target price of $6.88.
Shares of NASDAQ:NEOS opened at $1.41 on Thursday. The firm has a market capitalization of $70.11 million, a P/E ratio of -0.88 and a beta of 1.18. Neos Therapeutics has a 1 year low of $1.13 and a 1 year high of $6.30. The company has a quick ratio of 1.27, a current ratio of 1.49 and a debt-to-equity ratio of 41.70. The business’s 50 day moving average is $1.37.
Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.07. The company had revenue of $14.63 million for the quarter, compared to analyst estimates of $14.20 million. Sell-side analysts predict that Neos Therapeutics will post -0.61 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Alambic Investment Management L.P. bought a new stake in Neos Therapeutics during the first quarter worth $32,000. Rhumbline Advisers lifted its stake in Neos Therapeutics by 43.5% during the first quarter. Rhumbline Advisers now owns 53,730 shares of the company’s stock worth $140,000 after purchasing an additional 16,288 shares during the last quarter. BNP Paribas Arbitrage SA lifted its stake in Neos Therapeutics by 1,749.5% during the first quarter. BNP Paribas Arbitrage SA now owns 10,098 shares of the company’s stock worth $26,000 after purchasing an additional 9,552 shares during the last quarter. Livingston Group Asset Management CO operating as Southport Capital Management bought a new stake in Neos Therapeutics during the first quarter worth $63,000. Finally, Virtu Financial LLC bought a new stake in Neos Therapeutics during the first quarter worth $131,000. Hedge funds and other institutional investors own 54.87% of the company’s stock.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
Recommended Story: How is a Moving Average Calculated?
Get a free copy of the Zacks research report on Neos Therapeutics (NEOS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.